Ro's Better Than Clinic Experience
Ro
Ro won early because it turned an awkward, time consuming medical errand into a fast repeatable checkout flow with clinical review built in. For erectile dysfunction, hair loss, and herpes, the better product was not better medicine, it was skipping the search for a doctor, the waiting room, and the short visit, then getting treatment shipped discreetly at a price that could beat a normal co pay.
-
Roman and Hims both launched into erectile dysfunction in 2017, right after generic Viagra opened up a large cash pay market. The winning move was making the consult effectively free, then selling low cost generics on subscription, which cut the all in cost to around $10 per prescription versus typical co pays of $10 to $40.
-
The product advantage came from the workflow. Ro starts with structured online intake, lets clinicians review asynchronously, and handles renewal, fulfillment, and follow up in one loop. That works especially well in medication heavy categories where people need privacy and ongoing refills more than a one time diagnosis.
-
This wedge was powerful but narrow. Ro's early business was still dominated by Roman, about 60% of revenue in 2021, showing how much the initial fit came from a few high intent conditions. Later growth required moving into more complex categories like obesity, where deeper lab, pharmacy, and monitoring infrastructure matters more than simple convenience.
The next phase of direct to consumer telehealth belongs to companies that can turn this same better than clinic experience into longer care pathways. Ro is pushing in that direction through ro.OS, GLP-1 care, pharmacy integrations, and longitudinal monitoring, so the advantage shifts from discreet checkout and delivery toward running months of treatment with less friction than the traditional system.